Clinical Trial

A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 30, 2026 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-11; most recent amendment 2026-01-27.
Status change: Not Yet Recruiting → Recruiting 2026-01-27
Trial Details
NCT Number NCT07170800
Lead Sponsor WestVac Biopharma Co., Ltd.
Conditions Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Enrollment 60 participants
Start Date 2025-09-19
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-09-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-30